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Abstract
Background: Emerging evidence showed promising effects of vitamin D on headaches characteristics. Thus, it
seems there is still a need for more researches to clarify the mechanisms by which this vitamin exerts anti-migraine
effects.
Methods: The present study was conducted as a 16-week randomized double-blind placebo-controlled trial on 80
episodic migraine patients allocated in 2 parallel groups each consisted of 40 patients who received vitamin D
2000 IU/d or placebo. At baseline and after the intervention completion, headache diaries and migraine disability
assessment questionnaire (MIDAS) were used to assess migraine related variables in patients. Also, interictal serum
concentration of calcitonin gene-related peptide (CGRP) (as the dominant mediator of migraine pain pathogenesis)
was evaluated using ELISA method.
Results: The mean (SD) of age in the vitamin D and placebo groups was 37 (8) and 38 (12) years, respectively. ANCOVA
test adjusted for baseline values, and confounders showed vitamin D supplementation resulted in a significant
improvement in MIDAS score after 12 weeks in the intervention group (21.49 (16.22–26.77)) compared to placebo (31.16
(25.51–36.82) P value: 0.016). Moreover, after controlling for baseline levels, and other variables using ANCOVA, CGRP
level was appeared to be significantly lower following vitamin D supplementation (153.26 (133.03–173.49) ng/L) than the
patients in the placebo arm (188.35 (167.15–209.54) ng/L) (P value = 0.022).
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Conclusion: According to the current findings, vitamin D supplementation in episodic migraineurs, particularly in those
with migraine with aura, may potentially improve migraine headache characteristics and disability probably through
attenuating CGRP levels. Therefore, these results could provide a new insight into anti-nociceptive effects of vitamin D;
however, more studies are required to confirm our findings.
Trial registration: The trial is registered in the Iranian registry of clinical trials (IRCT) at 11 July 2018, with IRCT code:
IRCT20151128025267N6.
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Background
According to the report of global burden of disease
(GBD) 2016, migraine headache has been established as
the leading disability cause in the globe among under 50
years old [1]. It has been estimated that migraine affects
about 11% of adults with a major impact on those aged
between 25 to 55 years [1, 2], which consequently lead
to the high headache burden on individuals, communi-
ties, health care systems, and societies [3]. Migraine is
2–3 times more common in women than in men. Mi-
graine attacks are usually more prolonged, with higher
intensity and more disability among females [4].
Two main categories of migraine include episodic mi-
graine (having < 15 headache days per month) and
chronic migraine (having ≥15 headache days per month,
of which at least 8 days are with migraine features or re-
sponse to Triptans, for at least 3 months) [5]. If patients
who suffer from episodic migraine, especially those with
frequent attacks, are not treated appropriately, it can
lead to chronic type which is reported to be more severe
with higher disability [6, 7].
Both genetics and environment are supposed to be re-
lated to migraine development. Some dietary factors,
misuse of caffeine, hormonal fluctuations, high stress
level, increased weight, smoking, and suffering from ten-
sion type headache or medication overuse headache are
among the suggested factors affecting migraine suscepti-
bility and or chronification [8].
There is no established mechanism to explain mi-
graine pathogenesis, although there have been much ef-
forts directed in this field. The current evidence suggest
a variety of mechanisms which are thought to be in-
volved in pathophysiology of migraine including cortical
spreading depression (CSD), trigeminovascular pathway
activation (a pathway for nociceptive information con-
duction), neuro-inflammation as well as dysfunction in
vascular system [9]. Also, different neuropeptides such
as calcitonin gene-related peptide (CGRP), and pituitary
adenylate cyclase-activating peptide (PACAP) with vaso-
active properties are believed to be released during mi-
graine attacks. The release of these factors could affect
activation of trigeminovascular system and subsequently
might induce mast cells degranulation, vasodilatation of
arteries, and plasma leakage, which all are supposed to
be involved in migraine attacks initiation [9].
Current evidence highlighted a need for compounds
that suppress the neuro-inflammatory state in migraine
as novel effective medications in its treatment [8, 10,
11]. Keeping this in mind, adverse effects that related to
the present migraine pharmacological treatments (in-
cluding weight reduction or weight gain, fatigue/ sleepi-
ness, sweeting, night dreams, gastrointestinal upset,
hypotension or reduced concentration) might negatively
impact on the patients’ adherence to drug therapy, and
therefore reduce the efficacy of treatment procedure
[12–15]. Hence, applying novel therapeutic approaches
including nutritional agents could be promising strat-
egies that can favorably modify migraine characteristics
and its associated disability [8]. Magnesium, omega 3,
melatonin, coenzymes Q10, riboflavin and folate are
among the most studied dietary supplements that have
been suggested to be beneficial in prophylaxis of mi-
graine [16, 17]. Also, vitamin D is one of the dietary
agents that has been taken into consideration for pain
and migraine improvement [18–23]. In this regard, our
team has recently published a review paper aiming to
address the association between vitamin D and headache
[8]. It was estimated that about 45–100% of migraine or
headache patients might suffer from deficiency/insuffi-
ciency of vitamin D. It was further shown that there
seems to be a negative correlation between serum vita-
min D concentrations and headaches frequency [8].
Also, in our previous paper [24], we showed that supple-
mentation with vitamin D (2000 IU/d) could reduce
number of headache attacks, decrease the need for anal-
gesic consumption and attenuate intensity and duration
of headaches. We also observed that this vitamin might
suppress neuro-inflammation in migraineurs through
lowering the levels of inducible nitric oxide synthase
(iNOS) and probably interleukin (IL)-6 [24]. However, it
seems there is still a need to further clarify the mecha-
nisms by which vitamin D exerts anti-migraine effects.
Therefore, in the same study, we aimed to explore
changes in interictal levels of the dominant mediator of
migraine pain pathogenesis [25] (serum CGRP) following
prophylactic administration of vitamin D. In addition,
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vitamin D effects on migraine associated disability was
aimed to be determined.
Methods
Study design
The details on study design and data collection has been
described in our previous publication [24]. Briefly, the
present study was conducted as a 16-week (12-week
intervention following a 4-week baseline period) ran-
domized double-blind placebo-controlled trial on 80 epi-
sodic migraineurs aged between 18 and 45 years to
investigate the effects of 2000 IU/d vitamin D supple-
mentation on headache characteristics and CGRP levels
compared with placebo.
Participants and settings
The current randomized clinical trial (RCT) was performed
in Tehran, Iran from July 2018 to July 2019. Totally, 98 mi-
graine patients who were referred to the tertiary headache
clinic of Sina University Hospital, were interviewed for the
current trial. Inclusion criteria were diagnosis of episodic
migraine (EM) according to headache characteristics and
the International Classification of Headache Disorders, 3rd
edition (ICHDIII criteria) [5], age between 18 to 45 years,
having body mass index (BMI) between 18.5–30 kg/m2
and suffering from migraine for at least 6months prior to
study. Exclusion criteria were unwillingness to participate
in the study, suffering from medication overuse headache
in 3months prior to study, taking vitamin D supplements
in 3months prior to study, taking magnesium, calcium,
zinc, vitamin B groups or vitamin C supplements during
the study period, taking anti-epileptic drugs such as topira-
mate, sodium valproate and carbamazepine, taking thiazide
diuretics, glucocorticoid, statins or orlistat, taking anti-
psychotic drugs. Also, menopause, pregnancy and lactation,
and suffering from gastrointestinal disorders, liver and kid-
ney disorders, cancer, sarcoidosis, rickets, and osteomalacia
according to physician diagnosis and/or past medical his-
tory were among the other exclusion criteria.
Participants’ randomization and blinding
After initial examination by the study expert headache-
specialist neurologists, 32 subjects were excluded due to ex-
clusion criteria as illustrated in Fig. 1. From the beginning
Fig. 1 Flow-Diagram of Studied Patients
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of the study, A (vitamin D supplement) and B (placebo)
codes were available to the researchers to recruit the pa-
tients. Only one of the staff of headache department was
aware of codes. Block randomization was applied to ensure
that both participants and researchers were blind to treat-
ment allocation. Thus, 80 patients who fulfilled the inclu-
sion criteria were randomly allocated in a 1:1 ratio in
blocks of 4 to receive either A or B supplements and strati-
fied based on gender. Since assignment of patients was con-
cealed until statistical analysis completion, the participants,
neurologists, and investigators were blinded to the group
allocation throughout the trial.
Data collection
At the first visit, all demographic and socioeconomic in-
formation including age, sex, marital status, educational
status, and job, headache onset years, having migraine
with/without aura, familial history of migraine and smok-
ing status, number and type of medications, and data on
past medical history of patients were collected through
face to face interview by an expert researcher.
Anthropometric data including weight, and height
were also evaluated at study entry and the end of the
trial as follow: body weight was assessed to the nearest
0.5 kg and height to the nearest 0.1 cm applying a Seca
755 dial column medical scale and standard stadiometer,
respectively. BMI was calculated as weight in kilograms
divided by height in square meters.
Intervention
Patients in the intervention group received 1 pearl con-
taining 2000 IU of vitamin D/d in addition to routine
medications prescribed by our study neurologists. The
patients in the placebo group were given 1 placebo pearl
which was indistinguishable from vitamin D pearls in
taste and appearance. Throughout the trial, the subjects
were allowed to consume their usual acute/ prophylactic
drugs, though they were asked not to change their medi-
cations during the trial. Both vitamin D and placebo




All participants received a 30-days headache diary to fill
out the migraine characteristics (designed by the senior
researcher, Prf. M.T and has been described in details
previously) [26]. Briefly, the participants were asked to
complete their headache diaries during a month prior to
beginning the intervention and also the last month of
trial. Detailed results of present RCT on headache char-
acteristics based on these diaries have been reported pre-
viously [24]. To better understand current findings, we
only mentioned the results on the number of headache
days per month.
In addition, at the end of investigation we asked the
participants to roughly rate their overall perception of
headaches improvement following the current interven-
tion using a six-point Likert scale, ranging from 1 (less
than 10%) to 6 (more than 70%) [27].
Migraine disability assessment questionnaire (MIDAS)
At baseline and after the intervention completion,
MIDAS questionnaire was used to assess migraine re-
lated disability in patients. The questionnaire includes
seven questions that examine the levels of impact of
headaches on work, home, social and leisure activities
over the past 3 months. Questions 1 through 5 of this
questionnaire assess the migraine-related decline in per-
formance. The questionnaire was validated previously in
Iran [28].
Blood collection and serum analysis
At the first visit and the end of the trial, 5 ml blood sam-
ples were obtained from all the patients to assess serum
concentration of 25OHD and CGRP. Blood samples
were centrifuged at 4 °C for 10 min and serum samples
were kept at − 80 °C until laboratory analysis. Vitamin D
levels in the form of serum 25OHD (S25OHD) were
evaluated using chemiluminescence immunoassays
(CLIA) method. Serum level of CGRP was evaluated
using enzyme linked immunosorbent assay (ELIZA)
method and Crystal Day kit, E1061 Hu, 96 tests (Crystal
day, China). The interval of time from the last attack of
headache to the day of blood samples collection was also
recorded.
Compliance, adverse events and patients’ satisfaction score
Compliance was indicated using tablet count after 12-
week of intervention. A studied participant was considered
compliant if ≥70% of the tablets had been used throughout
the trial. During study follow-up, the compliance was add-
itionally stimulated by weekly telephone calls and remind-
ing the participants to use the supplements. Also, after 12-
week trial, S25OHD status was evaluated in order to as-
sess the compliance of the subjects in the intervention
arm. Also, patients were asked to report any minor or
major adverse effects which were likely to be associated
with supplementation. The subjects were also asked to
rate their satisfaction with participation in the study using
a five-point Likert scale ranging from 1 (very dissatisfied)
to 5 (very satisfied) [27].
Sample size calculation and statistical analysis
According to the below formula, it was assumed that by
estimating 40 samples in each group with an average of
8 headache day/month (standard deviation (SD): 4 days),
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aiming to detect at least 4 days reduction in headache
days, 90% statistical power will be achieved (α = 0.05,
β = 0.90, and S = 4 and d = 4) [19].






Means (SD) were used to describe the quantitative vari-
ables and frequencies (percentage, %) were reported for
categorical variables. Within and between groups compar-
isons were made using paired sample t-test or either inde-
pendent t test or Chi square test, respectively. Further,
one-way analysis of variance (ANOVA) was used to com-
pare between groups when aiming to assess variables
changes before and after supplementation with vitamin D
or placebo in episodic migraine patients with/without
aura. In order to analysis the effects of intervention on
headache characteristics, MIDAS score, and serum CGRP
levels, analysis of covariance (ANCOVA) adjusted for
baseline values and confounders was applied. In the case
of using ANCOVA, the adjusted means and 95% confi-
dence intervals (95% CI) were also reported. Pearson cor-
relation test was used to determine the correlation
between changes in S25OHD and outcome variables. The
figures was prepared by GraphPad Prism 5.0 (GraphPad
Software, Inc.). Significance level was defined as P < 0.05
level. All statistical analyses were performed using SPSS
program version 19 (IBM Corporation, New York, USA).
Results
Baseline, clinical and anthropometric characteristics
Figure 1 displays the studied subjects flow-diagram. Ini-
tially, 130 headache patients were examined by our study
headache-specialists of whom 32 had other types of head-
ache concurrent with migraine including cervicogenic
headache, or secondary headaches. Thus 98 migraineurs
were assessed for eligibility criteria of whom 80 were in-
cluded in the trial; and randomized into vitamin D (n = 40,
80.0% women) or placebo group (n = 40, 80.0% women).
Four subjects in the placebo group and 2 patients in the
intervention arm were lost to follow-up. The reasons are
described in Fig. 1.
Table 1 displays the baseline characteristics, and clinical
and anthropometric data of the studied participants. The
two studied groups did not differ significantly in age, sex,
headache onset years, socio-economic status, having mi-
graine with/without aura, familial history of migraine or
smoking status. The mean (SD) of age in the vitamin D
and placebo groups was 37 (8) and 38 (12) years, respect-
ively. On average, headache onset years in the patients in
the intervention and control group were about 12 and 11
years, respectively. Additionally, approximately 32.5% of
patients who received vitamin D supplements and 25.0% of
the placebo taking patients were suffering from migraine
with aura. The mean BMI was approximately around
25.83 kg/m2 in vitamin D group, and 25.36 kg/m2 in pla-
cebo group before and after the study, with no significant
differences between groups.
Serum vitamin D status
Mean baseline S25OHD levels among patients received
placebo was significantly higher than those in the vita-
min D group (P value = 0.017); however, after 12 weeks
of study, serum levels of this vitamin significantly in-
creased in the vitamin D group (from 27.31 to 39.65 ng/
ml; P value< 0.001) compared to no significant changes
observed in the placebo group (from 33.70 to 33.95 ng/
ml) (P value for between group comparison = 0.062).
Medications consumption
The medications consumption of both studied groups at
baseline and after the intervention consisted of abortive
and prophylactic drugs are demonstrated in Fig. 2. There
was not any significant differences between groups be-
fore and after the trial on type of abortive/prophylactic
medications use, except for using triptans in the placebo
group which was significantly higher than that of vita-
min D group after the trial (P = 0.024).
The number of headache days and frequency of attacks
Detailed results of present RCT on headache characteris-
tics have been reported previously [24]. Patients in treat-
ment and placebo group were estimated to experience
about 8.04 and 7.69 headache days per month, respect-
ively. No significant differences were noted regarding
baseline values of number of headache days between the
groups. Paired t-test revealed statistically significant re-
duction in the number of headache days among the pa-
tients who received vitamin D supplements (mean
changes: − 2.90 (3.03); P value< 0.001), whereas there
were no significant changes observed within the placebo
group when comparing to the baseline data. Following
the trial, ANCOVA test adjusted for baseline values and
confounders demonstrated that patients in vitamin D
group had significantly lower headache days (4.71 day/
month) in comparison with placebo group (6.43 day/
month) (P value from ANCOVA test =0.031).
Migraine disability
There were no significant differences in baseline MIDAS
scores in vitamin D and placebo groups (mean values =
29.75 and 36.87, respectively). Vitamin D supplementation
resulted in a significant improvement in MIDAS score
after 12 weeks in the intervention group (21.49 (16.22–
26.77)) compared to placebo (31.16 (25.51–36.82) P value
from ANCOVA test = 0.016)). Within group comparisons
revealed this score significantly reduced in vitamin D
group (mean changes: − 10.38 (12.29); P value< 0.001),
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while there were no significant changes noted within the
placebo group (Table 2).
Comparison between episodic migraine patients with or
without aura
Following 12 weeks of intervention, number of head-
ache days and disability score significantly decreased
in vitamin D treated migraine patients either those
with aura or without aura (P value≤0.002). Interest-
ingly, migraineurs with aura who received vitamin D
supplements had the highest reduction of mean fre-
quency of headache days per month (− 4.58) and
MIDAS score (− 16.92) as compared to other studied
groups (P value≤0.001) (Table 3).
Table 1 Baseline demographic, anthropometric and clinical data of episodic migraine patients in a randomized controlled trial of
vitamin D vs. placebo
Vitamin D (n = 40) Placebo (n = 40) P value#
Age (year) 37 (8) 38 (12) 0.819
Headache Onset years (year) 12 (8) 11 (8) 0.679
Body mass index (kg/m2) 25.83 (4.07) 25.36 (4.29) 0.613
Sex
Female 32 (80.0%) 32 (80.0%) 1.000
Male 8 (20.0%) 8 (20.0%)
Marital Status
Married 31 (77.5%) 26 (65.0%) 0.339
Single 9 (22.5%) 13 (32.5%)
Widow/widower 0 (0%) 1 (2.5%)
Educational Status
High school 13 (32.5%) 16 (40.0%) 0.293
BSc 11 (27.5%) 7 (17.5%)
MS 8 (20.0%) 13 (32.5%)
PhD and higher 8 (20.0%) 4 (10.0%)
Job
No job/house wife 12 (30.0%) 16 (40.0%) 0.480
Student 1 (2.5%) 3 (7.5%)
Employee 23 (57.5%) 17 (42.5%)
Self employed 4 (10.0%) 4 (10.0%)
Migraine Aura
Migraine with aura 13 (32.5%) 10 (25.0%) 0.459
Migraine without aura 27 (67.5%) 30 (75.0%)
Familial History of Migraine
Yes 26 (65.0%) 32 (80.0%) 0.133
No 14 (35.0%) 8 (20.0%)
Smoking Status
No 37 (92.5%) 35 (87.5%) 0.549
Yes 0 (0%) 1 (2.5%)
More than 5 cigarette per week 3 (7.5%) 4 (10.0%)
Less than 5 cigarette per week 0 (.0%) 0 (0%)
Values are expressed as mean (SD) or number (%) as appropriate
#Using either Independent t test or Chi square according to the type of data
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Patients’ overall perception of headaches improvement
About 17.5% (n = 7) and 10% (n = 4) of patients in the
vitamin D group reported 50–70% and > 70% overall im-
provement in their headaches, respectively; while majority
of patients in control group reported < 20% improvement
(P value < 0.001) (Fig. 3).
Serum analysis of CGRP levels
At baseline, mean time from the last attack to the day of
blood samples collection was reported to be about 4 days
in both vitamin D and placebo groups. At the end of
trial, mean days since the last attack was estimated as 5
days in vitamin D group and 4 days in placebo group.
The changes in serum concentrations of CGRP in two
studied groups before and after supplementation with
vitamin D or placebo are demonstrated in Table 2. At
baseline, patients in vitamin D group had a slightly
higher serum levels of CGRP (mean values = 195.27
and166.05 ng/L, respectively; P value = 0.063). Within
group comparisons showed CGRP levels significantly re-
duced in the vitamin D group compare to baseline
(mean changes: − 27.31 (59.69); P value = 0.006), while it
slightly increased in the placebo group (mean changes:
12.57 ± 23.85); P value = 0.004). After the trial, the results
of independent t test showed no significant differences
in mean CGRP concentration of the two studied group;
however, after controlling for baseline CGRP levels, age,
sex, BMI change, the years having headache, and time
from last attack using ANCOVA, CGRP level was ap-
peared to be significantly lower following vitamin D
supplementation among patients in the intervention
group (153.26 (133.03–173.49) ng/L) than the patients in
the placebo arm (188.35 (167.15–209.54) ng/L (P value:
0.022)).
Correlation between changes in S25OHD and headache
related variable
Figure 4 illustrates the Pearson correlation analysis be-
tween S25OHD changes and changes in the number of
headache days (Fig. 4a), changes in migraine disability
score (Fig. 4b) CGRP levels changes (Fig. 4c) over the 3-
month supplementation with 2000 IU/d vitamin D or
placebo. Non-significant negative correlations were de-
tected between changes in S25OHD and changes in
number of headache days per month (r = − 0.201, P
value = 0.094), MIDAS score (r = − 0.176, P value =
0.172), and CGRP levels (r = − 0.144, P value = 0.219)
throughout the intervention (Fig. 4).
Adverse effects and patients’ satisfaction
No statistically significant differences were observed be-
tween the studied groups with regard to the total number
of patients experienced adverse effects over the trial.
Minor gastrointestinal complaints were the most reported
adverse effects among both groups with 5 patients (12.5%)
in vitamin D group and 8 patients (22.2%) in controls.
None of the studied subjects reported any serious adverse
reactions, and the interventions overly were well-tolerated.
The median score of patients’ satisfaction with the trial
Fig. 2 Types of Medications Used By Studied Patients Throughout The Trial. NSAIDs, Nonsteroidal anti-inflammatory drugs. TCAs, Tricyclic
antidepressants. SSRIs, Selective serotonin reuptake inhibitors. SNRIs, Serotonin-Norepinephrine Reuptake inhibitors
Ghorbani et al. The Journal of Headache and Pain           (2020) 21:22 Page 7 of 13
Table 3 Changes in number of headache days, and migraine disability scores before and after supplementation with vitamin D or
placebo in episodic migraine patients with/without aura
Study sub-groups P value*
Patients with migraine with aura Patients with migraine without aura
Vitamin D Placebo Vitamin D Placebo
Number of Headache Days per month
Baseline 10.58 (3.67) a,b 7.75 (3.86) 6.81 (2.43) a 7.67 (3.29) b 0.008
After the trial 6.00 (3.45) 7.50 (3.32) 4.63 (2.40) a 7.17 (4.11) a 0.029
Changes −4.58 (3.76) a,b −0.25 (3.05) a −2.09 (2.27) − 0.10 (2.91) b 0.000
P value# 0.001 0.801 < 0.001 0.868
Migraine Related Disability (MIDAS score)
Baseline 40.00 (26.38) 37.90 (18.53) 24.81 (10.80) 36.53 (22.75) 0.057
After the trial 23.08 (24.42) 42.90 (25.15) a 17.59 (10.94) a.b 32.46 (16.44) b 0.001
Changes −16.92 (15.39) a,b 5.00 (20.18) a −7.22 (9.25) −1.46 (12.20) b 0.001
P value# 0.002 0.453 < 0.001 0.547
Data are presented as mean (standard deviation)
Alphabets represent significant differences between each variable and two other variables, calculated by Bonferroni test (post-hoc)
*One-way analysis of variance (ANOVA)
# Paired sample t-test
Table 2 Changes in migraine characteristics, the use of analgesics and serum CGRP levels before and after supplementation with
vitamin D or placebo in episodic migraine patients






Baseline After 12 Weeks Baseline After 12 Weeks
Serum 25OHD Levels (ng/ml)
Mean (SD) 27.31 (12.30) 39.65 (13.45) 33.70 (11.08) 33.95 (12.14) 0.017 0.062£
Changes from baseline 12.34 (6.34) −0.28 (5.90)
P value for within-group comparison < 0.001# 0.782#
Number of Headache Days per month
Mean (SD) 8.04 (3.35) 5.07 (2. 82) 7.69 (3.39) 7.26 (3. 86) 0.644 0.006£
Adjusted mean (95%CI) 4.71 (3.64–5.77) 6.43 (5.28–7.58) 0.031 δ
Changes from baseline −2.90 (3.03) - 0.14 (2.91)
P value for within-group comparison < 0.001# 0.776#
Migraine Related Disability (MIDAS score)
29.75 (18. 54) 19.38 (16. 43) 36.87 (21. 55) 35.36 (19. 45) 0.117 < 0.001£
Adjusted mean (95%CI) 21.49 (16.22–26.77) 31.16 (25.51–36.82) 0.016 δ
Changes from baseline −10.38 (12.29) 0.33 (14. 82)
P value for within-group comparison < 0.001# 0.893#
Serum CGRP levels (ng/L)
Mean (SD) 195.27 (78.45) 167.961 (80.112) 166.05 (58.32) 176.71 (72.22) 0.063 0.626£
Adjusted mean (95%CI) 153.26 (133.03–173.49) 188.35 (167.15–209.54) 0.022 €
Changes from baseline −27.31 (59.69) 12.57 (23.85)
P value for within-group comparison 0.006# 0.004#
P value < 0.05 was considered significant
The second row of this table was previously published in [24] in a slightly different format
BMI Body mass index, MIDAS Migraine disability assessment questionnaire, CGRP Calcitonin gene-related peptide
#Paired sample t-test
£ Independent t-test
δANCOVA test adjusted for baseline values, age, sex, and BMI change
€ANCOVA test adjusted for baseline CGRP levels, age, sex, BMI change, the years having headache, and time from last attack
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was higher among vitamin D receiving patients (median =
3) than placebo groups (median = 2) (P value: 0.003).
Discussion
In our previous report of present RCT, it was first demon-
strated that 12-week supplementation with vitamin D
2000 IU/d resulted in significantly lower headache days,
and attacks frequency [24]. Further analysis in current
study, showed that following adjustment for confounding
factors (i.e. baseline disability level, sex, age, and BMI
change) using ANCOVA, vitamin D is shown to signifi-
cantly decrease migraine related disability in comparison
with placebo group. Interestingly, these results were espe-
cially pronounced among those patients who had migraine
with aura. Current study may be considered a further ef-
fort in clarifying the mechanisms through which vitamin
D might be effective in migraine prophylaxis. In this re-
gard, it is demonstrated that following the trial, mean
interictal level of CGRP in patients who received 2000 IU/
d of vitamin D was significantly lower than that of placebo
receiving group.
These results tie well with most of the previous studies
wherein vitamin D supplementation effects were investi-
gated in relation to pain, headache or migraine [8, 29–33].
According to the recently published review article, there
have been numerous studies that reported a positive link-
age between vitamin D deficiency and pain associated
conditions; however, no causal relationship has been
noted yet [8]. There are also clinical studies that have
found vitamin D supplementation may result in pain re-
lieving effects particularly among the subjects who had
S25OHD concentration less than 30 nmol/L [29–33].
There are several likely mechanisms that may explain
the protective effects of vitamin D on migraine charac-
teristics and associated disability. First, according to
current results, administration of this vitamin signifi-
cantly reduced serum CGRP levels, the dominant medi-
ator [25] of migraine pain. To our knowledge current
study results regarding the effects of vitamin D on CGRP
are novel, therefore we cannot directly compare them
with previous studies.
CGRP is a vasoactive neuropeptide containing 37 amino
acids that plays a role in vasodilation, modulating immune
system, neuronal inflammation and transmission of pain
signals. Two main isoforms of CGRP are alpha-CGRP
(which is certainly found in both peripheral and central
nervous system (PNS and CNS)) and beta-CGRP (which
is mainly present in enteric nervous system), only differ in
Fig. 3 Patients Overall Perception of Headache Improvement Following 12-week Trial. (P value< 0.001)
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3 amino acid constituents [34]. The sensory nerve fibers
that contain CGRP are particularly expressed in neuronal
and vascular tissues of the cerebrum, specifically in the tri-
geminal ganglion. This neuropeptide could induce direct
vasodilatation (independent of endothelium) through
binding to the receptors (CGRP-1, CGRP-2, CGRP-3) and
stimulating the release of adenyl cyclase and cyclic adeno-
sine monophosphate (cAMP). It is thought that serotoner-
gic system regulate CGRP secretion while nerve growth
factor and NO affect its production. Additionally, CGRP is
highly interacted with substance P (SP) such that both
neuropeptides could usually be found in the same sites of
nervous system [25, 34, 35]. As one of the most studied
factors in relation to migraine, CGRP is contributed to a
variety of pathophysiological mechanisms involved in pain
sensitization in this type of headache. Inducing dilation in
the blood vessels of dura matter, causing degranulation of
mast cells and above all, playing a pivotal role in activation
of trigeminovascular system which is responsible for noci-
ceptive information conduction from the meninges to the
cortex and central region of the brain, are among the sug-
gested mechanisms [34].
The CGRP concentration is detected to be augmented in
migraineurs especially during head pain periods [34, 36].
These evidences can further confirm the hypothesis of rec-
ognizing migraine as a neuro-vascular disorder and also
support the potent role of CGRP and neural events that
cause dilation in blood vessels in migraine pathogenesis
[34, 36]. In most of the subjects who had a history of mi-
graine, a delayed migraine attack occurs following CGRP
administration in IV form; while CGRP administration in
healthy subjects did not result in pain sensitization includ-
ing headache or somatic pain. Therefore, it seems that
CGRP could not directly cause migraine pain and may
mainly impose its effects via induction of different path-
ways such as stimulating the production of nitric oxide
(NO), that finally could lead to neuro-inflammation and
vasodilation which both might be involved in migraine
pain [25, 36]. CGRP in combination with SP, PACAP, glu-
tamate and neuropeptide Y could also induce a neurogenic
inflammatory state in the CNS especially in trigeminovas-
cular system. This inflammatory state is thought to be con-
tributed to migraine pain sensation. Nonetheless, the
activation of trigeminal pathway could also provoke the re-
lease of these factors and particularly might increase CGRP
and SP secretion [9, 10, 25, 34, 35, 37–40].
To our knowledge this is the first investigation in migrai-
neurs that assessed the levels of CGRP following vitamin D
Fig. 4 a The Correlation between changes in serum 25OHD and number of headache days per month throughout 12-week trial. b The Correlation
between changes in serum 25OHD and migraine related disability score (MIDAS, migraine Disability Assessment score) throughout 12-week trial. c The
Correlation between changes in serum 25OHD and CGRP (calcitonin gene-related peptide) levels throughout 12-week trial
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supplementation. According to available evidence, the
mechanisms through which vitamin D influence CGRP
synthesis and or release have not been clearly defined yet.
There are a number of studies in which the effects of vita-
min D or its derivatives on CGRP concentration were eval-
uated in animal models or cell cultures in different
conditions; however, the findings have been inconclusive
[41–43] due, in part, to the animal models applied or the
dosage/duration of vitamin D administration.
In the present research, it was found that patients in
the intervention group had significantly lower S25OHD
levels, and on the other hand, a slightly higher serum
CGRP levels at baseline; however, supplementation with
the vitamin resulted in significant increment of S25OHD
and reduction of CGRP, though we did not find any
dose-response correlation throughout the trial between
either of headache related parameters (e.g. frequency of
headache days, MIDAS score or serum CGRP levels)
and S25OHD. Therefore, it is likely that the protective
effects of vitamin D in ameliorating migraine related fea-
tures and CGRP levels reduction may be attributed to its
anti-nociceptive properties and some indirect pathways.
It is worth noting that NO, might elevate CGRP and SP
synthesis/secretion release that ultimately may result in
triggering nociceptive neurons and inflammation spe-
cially in trigeminovascular system [25, 34, 35, 39, 44].
On the flip side, decreased vitamin D concentration has
been linked to elevated levels of NO. The protective effi-
cacy of this vitamin against endothelial dysfunction as
well as cardiovascular system could also be explained
through this inverse relationship between NO and
S5OHD levels [45]. Further, glutathione (GSH) presence
in astrocytes may be associated with nitrogen and oxy-
gen reactive species eliminating procedure (such as NO)
[46, 47]. Since vitamin D active form (1,25(OH)2D3)
may be involved in GSH metabolism, it can be specu-
lated that vitamin D may also be involved in NO metab-
olism pathway [8].
Study limitations
The strengths of this study are the prospective- double
blind, placebo- controlled design, using a safe daily dosage
of vitamin D as a somewhat inexpensive and available over-
the-counter supplement, exploring CGRP levels as the
dominant indicator of migraine pathogenesis, enrolling the
study participant following examinations by expert
headache-specialist neurologists, and confirming episodic
migraine diagnosis based on the most recent ICHD criteria
(ICHDIII). In spite of these strengths, there were a number
of limitations. First of all, due to ethical considerations and
according to migraine trials guidelines [27], it was not pos-
sible to discontinue the patients concomitant pharmaco-
logical therapy (including prophylactic or acute drugs).
However, patients were recommended not to change their
medications during the study. Also those subjects who re-
ceived the medications that are supposed to interact with
vitamin D were excluded from the trial. Second, although
we tried to consider the effects of some confounding fac-
tors on the influences of vitamin D supplementation on
headache outcomes through the ANCOVA, there might
still be some other factors that could have been taken into
account. Third, although both cases and controls were se-
lected from the same population with similar characteristics
including demographic, anthropometric and socioeco-
nomic status, there could still be a chance of bias. Further,
the current study was not powered enough to conduct a
subgroup analysis between those with vitamin D defi-
ciency/insufficiency. Thus, in future trials, subjects could be
categorized according to S25OHD status so that appropri-
ate dosage adjustment of vitamin D can be made. Addition-
ally, investigating the efficacy of vitamin D on subgroups of
migraine patients can be considered in the future trials in-
cluding those with menstrual related migraine, chronic mi-
graine or migraine with/without aura. Also, the effect of
vitamin D receptor gene polymorphism should be clarified
when studying the potential role of vitamin D supplemen-
tation in improvement of migraine characteristics and dis-
ability level.
Conclusion
According to the current findings, vitamin D supple-
mentation may potentially improve migraine headache,
which has been established as the leading cause of dis-
ability in < 50 years, probably through attenuating CGRP
levels. Therefore, daily administration of vitamin D 2000
IU as an adjuvant therapy could be considered a well-
tolerated and effective agent in improvement of migraine
characteristics and disability level particularly among
those patients who have migraine with aura. This could
provide a new insight into anti-nociceptive effects of
vitamin D. However, to confirm current promising find-
ings, large sample size RCTs with longer duration of
follow-up are required especially in patients with chronic
migraine. Also, well-designed animal and/or clinical
studies addressing the mechanisms through which vita-
min D may influence migraine pathogenesis, are of cru-
cial importance.
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